Showing 781 - 800 results of 224,793 for search '(( 50 ((ng decrease) OR (we decrease)) ) OR ( 10 ((a decrease) OR (nn decrease)) ))', query time: 1.25s Refine Results
  1. 781
  2. 782
  3. 783

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  4. 784

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  5. 785
  6. 786

    The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin... by Chanel Avenant (409756)

    Published 2025
    “…Both contraceptives substantially decreased, from D0 to 25W, the total testosterone [DMPA-IM D0 0.560, 25W 0.423 nmol/L, -24.3% (p < 0.0001); NET-EN D0 0.551, 25W 0.253 nmol/L, -54.1%, (p < 0.0001)], SHBG [DMPA-IM D0 45.0, 25W 32.7 nmol/L, -29.8% (p < 0.0001); NET-EN D0 50.2, 25W 17.6 nmol/L, -65.1% (p < 0.0001)], and calculated free testosterone levels [DMPA-IM D0 6.87, 25W 5.38 pmol/L, -17.2% (p = 0.0371); NET-EN D0 6.00, 25W 3.70, -40.0% (p < 0.0001)]. …”
  7. 787
  8. 788
  9. 789
  10. 790
  11. 791

    Forced WNT10A expression and WNT10A siRNA knockdown in kidney cell lines. by Ren-Jun Hsu (127121)

    Published 2012
    “…Conversely, RCC-1 and Caki-1 transfected with WNT10A siRNA showed significant decrease in cell proliferation as compared to cells transfected with reagent and scrambled siRNA controls. …”
  12. 792

    Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease by Nguyen Quoc Thai (5348798)

    Published 2018
    “…Moreover, the compound dose-dependently decreases β-site amyloid precursor protein cleaving enzyme (BACE-1) activity with EC<sub>50</sub> value in micromolar range. …”
  13. 793

    Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease by Nguyen Quoc Thai (5348798)

    Published 2018
    “…Moreover, the compound dose-dependently decreases β-site amyloid precursor protein cleaving enzyme (BACE-1) activity with EC<sub>50</sub> value in micromolar range. …”
  14. 794
  15. 795
  16. 796

    Resveratrol decreases proliferation of Cisplatin-sensitive A2780 cells but not Cisplatin-resistant A2780CP cells. by Sébastien Baribeau (512869)

    Published 2014
    “…<p>MTT assay was performed to evaluate A2780 and A2780 cell lines proliferation in response to 10 µM Cisplatin and increasing doses up to 60 µM of Resveratrol. …”
  17. 797

    Loss of <i>flp-1</i> decreases the nose touch response. by Ingrid Buntschuh (4729536)

    Published 2018
    “…<p>All <i>flp-1</i> and <i>daf-10</i> mutant alleles showed a decreased nose touch response. …”
  18. 798
  19. 799
  20. 800